Compare LH & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LH | INSM |
|---|---|---|
| Founded | 1971 | 1988 |
| Country | United States | United States |
| Employees | 70000 | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.7B | 23.0B |
| IPO Year | 2005 | 2000 |
| Metric | LH | INSM |
|---|---|---|
| Price | $255.36 | $95.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 24 |
| Target Price | ★ $311.33 | $201.17 |
| AVG Volume (30 Days) | 512.3K | ★ 3.7M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.12% | N/A |
| EPS Growth | ★ 18.33 | N/A |
| EPS | ★ 3.35 | N/A |
| Revenue | ★ $13,951,700,000.00 | N/A |
| Revenue This Year | $8.26 | $182.31 |
| Revenue Next Year | $4.81 | $65.19 |
| P/E Ratio | $76.33 | ★ N/A |
| Revenue Growth | ★ 7.25 | N/A |
| 52 Week Low | $241.81 | $90.39 |
| 52 Week High | $293.72 | $212.75 |
| Indicator | LH | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 42.18 | 38.07 |
| Support Level | $248.61 | $90.39 |
| Resistance Level | $274.48 | $166.81 |
| Average True Range (ATR) | 5.90 | 5.25 |
| MACD | -0.43 | 0.88 |
| Stochastic Oscillator | 12.60 | 32.99 |
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.